Short answer
Design Therapeutics, Inc. (DSGN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Design Therapeutics’ financial results for the three and nine months ended September 30, 2026.
Design Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Design Therapeutics’ financial results for the three and nine months ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $20.3M, or $0.32 per share, versus $17.0M and $0.30 in Q3 2025
- R&D spending rose to $16.9M from $14.6M, reflecting increased clinical development investment
- Cash and securities $208.6M at September 30, down from $219.8M at year-end 2025, supporting ongoing operations
- DT-216P2 registrational-plan update expected in Q4 2026, with 12-week RESTORE-FA data targeted for Q1 2027
- DT-818 DM1 and DT-168 FECD clinical data expected in 2027, creating multiple pipeline catalysts beyond DT-216P2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Design Therapeutics, Inc. 8-K filings
Get the next DSGN 8-K as it lands
Follow DSGN for push alerts, or ask the research agent what this filing means.